Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences
On November 11, 2021, Lyra Therapeutics (Nasdaq: LYRA) announced that CEO Maria Palasis, Ph.D., will present at three upcoming virtual investor conferences. These include the Jefferies London Healthcare Conference (available on-demand from November 18, 2021), the Canaccord Genuity Virtual MedTech Forum (on November 18, 2021), and the Evercore ISI HealthCONx Virtual Conference (on December 1, 2021). Webcasts will be accessible on the company's website for 30 days post-event. Lyra focuses on delivering localized treatments via its XTreo™ platform, targeting chronic rhinosinusitis and other ENT conditions.
- None.
- None.
WATERTOWN, Mass., Nov. 11, 2021 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D., Lyra's President and Chief Executive Officer, will present in a virtual format at three upcoming investor conferences:
The Jefferies London Healthcare Conference – on-demand fireside chat available beginning November 18, 2021 at 3:00 a.m. ET
The Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum – corporate presentation on November 18, 2021 at 9:00 a.m. ET
The Evercore ISI 4th Annual HealthCONx Virtual Conference – fireside chat on December 1, 2021 at 3:55 p.m. ET
Webcasts of the virtual presentations will be available in the Investor Relations section of the Company's website at https://investors.lyratherapeutics.com at the times and dates specified above. Webcast replays will be available for 30 days following each event.
About Lyra Therapeutics
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches. Lyra's XTreo™ platform is comprised of a biocompatible mesh scaffold, an engineered elastomeric matrix and a versatile polymer-drug complex. The company's current pipeline of therapeutics target tissues deep in the ear, nose and throat passages and are designed to deliver continuous drug therapy for up to six months following a single non-invasive, in-office administration. Lyra's lead product candidate, LYR-210, is entering Phase 3 clinical development for the treatment of chronic rhinosinusitis (CRS) as an alternative to primary sinus surgery. Lyra's second product candidate, LYR-220, is entering Phase 2 development and is designed to be an alternative to revision CRS sinus surgery and post-surgical medical management. For more information, please visit www.lyratherapeutics.com and follow us on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the date and time of each presentation and the company's pipeline. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the fact that the company has incurred significant losses since inception and expects to incur losses for the foreseeable future; the company's need for additional funding, which may not be available; the company's limited operating history; the fact that the company has no approved products; the fact that the company's product candidates are in various stages of development; our the fact that the company may not be successful in its efforts to identify and successfully commercialize its product candidates; the fact that clinical trials required for the company's product candidates are expensive and time-consuming, and their outcome is uncertain; the fact that the FDA may not conclude that certain of the company's product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway; the company's inability to obtain required regulatory approvals; effects of recently enacted and future legislation; the possibility of system failures or security breaches; effects of significant competition; the fact that the successful commercialization of the company's product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies; failure to achieve market acceptance; product liability lawsuits; the fact that the company relies on third parties for the manufacture of materials for its research programs, pre-clinical studies and clinical trials; the company's reliance on third parties to conduct its preclinical studies and clinical trials; the company's inability to succeed in establishing and maintaining collaborative relationships; the company's reliance on certain suppliers critical to its production; failure to obtain and maintain or adequately protect the company's intellectual property rights; failure to retain key personnel or to recruit qualified personnel; difficulties in managing the company's growth; effects of natural disasters; the fact that the global pandemic caused by COVID-19 could adversely impact the company's business and operations, including the company's clinical trials; the fact that the price of the company's common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company and any securities class action litigation. These and other important factors discussed under the caption "Risk Factors" in the company's Quarterly Report on Form 10-Q filed with the SEC on November 9, 2021 and its other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.
Investor Contact:
Argot Partners
212-600-1902
lyra@argotpartners.com
Media Contact:
Kathryn Morris
914-204-6412
kathryn@theyatesnetwork.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/lyra-therapeutics-to-present-at-upcoming-virtual-investor-conferences-301421717.html
SOURCE Lyra Therapeutics, Inc.
FAQ
What are the details of the upcoming conferences for Lyra Therapeutics (LYRA)?
Where can I find the webcasts for Lyra Therapeutics' presentations?
What is the focus of Lyra Therapeutics' XTreo™ platform?
What is the pipeline of Lyra Therapeutics as of November 2021?
When are the presentations scheduled for Lyra Therapeutics (LYRA)?
